Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 4

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 4
---
 conditions prevailing from time to time in such countries.

On November 21, 2024, the
Company received a notice from the Staff of Nasdaq notifying the Company that its securities are subject to delisting due to the MVPHS
Deficiency and MLVS Deficiency. The Company requested a hearing to appeal the delisting determination before the Nasdaq Hearings Panel
(the “Panel”) on November 27, 2024. On November 29, 2024, the Company received a formal notice from Nasdaq that the Panel
will consider its appeal at an oral hearing on January 28, 2025 (the “Hearing”). On February 19, 2025, the Company
received written decision from the Panel, which granted an extension, allowing the Company additional time to regain compliance with the
Nasdaq Stock Market’s continued listing requirements, subject to meeting specific compliance criteria within designated timeframes.
As of the date of this prospectus, in accordance with the Panel’s extension, the Company has already made progress on its compliance
plan, including carrying out a 1-for-20 reverse stock split of its issued and unissued shares which was effected on February 11, 2025.
The effect of the reverse stock split was to consolidate every 20 issued and unissued share into one share. On February 27, 2025, the
Company received a notification letter from Nasdaq, indicating that the closing bid price of the Company’s securities had been at
$1.00 per share or greater for 10 consecutive business days from February 11, 2025 to February 26, 2025, and the Company had regained
compliance with the minimum bid price rule. In addition, on February 27, 2025, the Company received a confirmation from Nasdaq that its
application to transfer its listing to the Nasdaq Capital Market had been approved and that the Company’s securities would be transferred
to the Nasdaq Capital Market at the opening of business on February 28, 2025.

Investing in our Class A Ordinary Shares involves a high degree of risk, including the risk of losing your entire investment. See “ Risk Factors” starting on page 25 to read about the factors you should consider before buying the Ordinary Shares.

Neither the Securities and Exchange Commission, or the SEC, nor any state or other foreign securities commission has approved nor disapproved these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal